Lloyd Carney

October 16, 2026

Visa gains record as investors rotate to defensive stocks. Visa and Mastercard posted record highs as investors shifted from chip stocks to more defensive names. The companies have asked a court to approve a fee settlement that could affect their transaction revenue. At the same time, Visa is preparing for a stablecoin payout service, which may broaden its payment offerings. These developments come as the stock trades near the top of its 52‑week range.

October 16, 2026

GDYN Receives Sysco Partner of the Year Award. GDYN was named Sysco's Partner of the Year, highlighting its role in Sysco's supply chain solutions. A Yahoo article also listed GDYN as a small‑cap stock worth attention, underscoring growing investor interest. The recognition may reinforce GDYN's market position and visibility among peers. The award and coverage come as the stock trades near the lower end of its 52‑week range.

October 17, 2026

Vertex Highlights Sickle Cell Gene Therapy and Hormone Disorder Expansion. Vertex Pharmaceuticals is advancing a gene therapy for sickle cell disease, which could broaden its treatment portfolio but faces access challenges. The company also signals a potential new growth area in hormone disorders, moving beyond cystic fibrosis. With earnings approaching, investors are watching how these developments affect the company’s outlook. The stock has risen above the market recently, reflecting positive sentiment.